Which antiretroviral (HIV) drugs have minimal or no intrinsic hepatotoxicity?

Non-Hepatotoxic HIV Drugs

For patients requiring antiretroviral therapy with minimal hepatotoxicity risk, integrase strand transfer inhibitors (InSTIs)—specifically dolutegravir and bictegravir—combined with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) plus emtricitabine or lamivudine represent the safest options with the lowest intrinsic hepatotoxic potential.

Recommended Low Hepatotoxicity Regimens

Based on the most recent 2024 IAS-USA guidelines 1 and 2018 recommendations 2, the following regimens have minimal hepatotoxicity:

First-Line InSTI-Based Regimens (Lowest Risk):

• Bictegravir/TAF/emtricitabine 2
• Dolutegravir/abacavir/lamivudine (requires HLA-B*5701 testing) 2
• Dolutegravir plus TAF/emtricitabine 2
• Dolutegravir/lamivudine (2-drug regimen) 1, 3

These InSTI-based regimens demonstrate minimal hepatotoxicity across contemporary studies 4, 5.

Alternative Low-Risk Options:

• Raltegravir plus TAF (or TDF)/emtricitabine 2
• Elvitegravir/cobicistat/TAF (or TDF)/emtricitabine 2
• Rilpivirine/TAF (or TDF)/emtricitabine (if HIV RNA <100,000 copies/mL and CD4 >200/μL) 2

Drugs to AVOID for Hepatotoxicity Concerns

Highest Hepatotoxicity Risk:

Nevirapine carries the greatest hepatotoxicity risk among all antiretrovirals:

• 12.5% incidence of hepatotoxicity, with 1.1% developing clinical hepatitis 6
• 9.4% experienced grade 4 liver enzyme elevation (vs. 0% with efavirenz) 6
• Two deaths from liver failure reported in clinical trials 6
• Risk doubles in females (12% vs. 6% in males) 6
• Can cause fulminant hepatic necrosis within days 6
• Never use nevirapine in patients with hepatotoxicity concerns 6

Moderate-High Hepatotoxicity Risk:

Protease Inhibitors (PIs):

• Ritonavir and ritonavir/saquinavir combinations show highest severe hepatotoxicity rates among PIs 6
• Indinavir, nelfinavir, and saquinavir have lower but still notable risk 6
• PI-associated hepatotoxicity can occur at any time during treatment (unlike nevirapine's early onset) 6

Older NRTIs:

• Stavudine and didanosine carry significant hepatotoxicity risk through mitochondrial toxicity 7
• Can cause hepatic steatosis with lactic acidosis (rare but serious) 6

Key Clinical Considerations

Risk Factors That Amplify Hepatotoxicity:

• Hepatitis C coinfection (major risk factor for PI hepatotoxicity) 6
• Hepatitis B coinfection 6
• Alcohol abuse 6
• Baseline elevated liver enzymes 6
• Concomitant hepatotoxic medications 6

Monitoring Strategy:

For patients on any antiretroviral therapy with liver disease risk factors:

• Baseline liver function tests before starting ART 2
• Monitor transaminases every 3 months during treatment 6
• If using nevirapine (not recommended): monitor every 2 weeks for first month, then monthly for 12 weeks 6

Contemporary Safety Data:

Recent evidence confirms that newer antiretrovirals (doravirine, ibalizumab, fostemsavir, cabotegravir) show minimal substantial hepatotoxicity risk 4. InSTIs and entry inhibitors demonstrate the lowest hepatotoxicity rates among all drug classes 7.

Practical Algorithm

For patients WITHOUT liver disease: Use any recommended InSTI-based regimen from 2024 guidelines 1

For patients WITH chronic liver disease or hepatitis coinfection:

1. Preferred: Dolutegravir or bictegravir + TAF/emtricitabine
2. Avoid completely: Nevirapine, stavudine, didanosine
3. Use with caution: Ritonavir-boosted PIs (only if InSTIs contraindicated)
4. Monitor: Liver enzymes every 1-3 months

If hepatotoxicity develops on ART:

• Discontinue offending agent immediately 6
• Switch to InSTI-based regimen if not already using one
• Never rechallenge with nevirapine if it caused severe hepatotoxicity 6